Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 7Unknown 3Completed 3Withdrawn 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 37Melanoma 17Prostatic Neoplasms 16Lung Neoplasms 14Neoplasms 13Squamous Cell Carcinoma of Head and Neck 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 9Precancerous Conditions 8Lymphoma 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Leukemia 6Esophageal Neoplasms 6Colorectal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms, Male 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Follicular 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Barrett Esophagus 5Adenocarcinoma Of Esophagus 5Salivary Gland Neoplasms 4Recurrence 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 35Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 16Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × Biopsy × Clear all
NCT03429816 2025-03-27

OPPOSITE

University Hospital Heidelberg

Phase NA Completed
120 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT02332213 2018-08-21

VOLGACORE

University of Latvia

Completed
2,022 enrolled
Gastrointestinal

Adenoma, Gastritis, Atrophic, Gastrointestinal Neoplasms, Peptic Ulcer, Stomach Neoplasms, Colorectal Neoplasms

NCT00397904 2015-11-25

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
16 enrolled 6 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡